☆ 4.4 Article

A low total metabolic tumor volume independently predicts for a longer time to first treatment in initially observed, low tumor burden follicular lymphoma

HEMATOLOGICAL ONCOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines tor diagnosis, treatment and follow-up

M. Dreyling et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Hematology

Clinicopathological factors and tumor microenvironment markers predicting watch-and-wait discontinuation in 82 patients with follicular lymphoma

Sayako Yuda et al.

Summary: The study aimed to determine the clinicopathological factors influencing the treatment-free period in patients with follicular lymphoma using a watch-and-wait strategy. Results showed that FLIPI score, numbers of interfollicular CD4(+) and intrafollicular FOXP3(+) cells, and Ki-67 index were significant adverse factors for WW discontinuation. Patients with these adverse factors should be carefully observed during follow-up.

EUROPEAN JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Article Oncology

Prognostic ability of five clinical risk scores in follicular lymphoma: A single-center evaluation

Pablo Mozas et al.

Summary: This study evaluated the clinical utility and statistical performance of the five most widely used clinical scores in FL patients. Although all scores showed predictive value in various outcomes, FLIPI was the most powerful in predicting endpoints.

HEMATOLOGICAL ONCOLOGY (2021)

Add to Collection

Article Hematology

Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma

Karthik Nath et al.

Summary: In patients with follicular lymphoma, low intratumoral T cells are associated with higher TMTV, and nodes with high TMTV exhibit increased malignant B-cell infiltration and fewer clonally expanded T-follicular helper cells. Additionally, CD4(+) and CD8(+) T cells demonstrate higher fluorescently labeled glucose uptake compared to intratumoral B cells.

BLOOD ADVANCES (2021)

Add to Collection

Article Hematology

Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy

Farheen Mir et al.

AMERICAN JOURNAL OF HEMATOLOGY (2020)

Add to Collection

Article Oncology

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

Emmanuel Bachy et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Hematology

Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma

Marie-Helene Delfau-Larue et al.

BLOOD ADVANCES (2018)

Add to Collection

Article Hematology

Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group

Sara Alonso-Alvarez et al.

BRITISH JOURNAL OF HAEMATOLOGY (2017)

Add to Collection

Article Hematology

Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era

Loretta J. Nastoupil et al.

BRITISH JOURNAL OF HAEMATOLOGY (2016)

Add to Collection

Article Oncology

Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies

Michel Meignan et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection

Article Hematology

A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait

Tarec Christoffer El-Galaly et al.

BRITISH JOURNAL OF HAEMATOLOGY (2015)

Add to Collection

Article Oncology

Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

Carla Casulo et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Add to Collection

Review Hematology

Survival analysis in hematologic malignancies: recommendations for clinicians

Julio Delgado et al.

HAEMATOLOGICA (2014)

Add to Collection

Article Oncology

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

Bruce D. Cheson et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

Add to Collection

Article Oncology

The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi

S. Luminari et al.

ANNALS OF ONCOLOGY (2013)

Add to Collection

Article Oncology

Watchful Waiting in Low-Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database

Philippe Solal-Celigny et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

Add to Collection

Article Oncology

Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98

Giovanni Martinelli et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

Add to Collection

Article Oncology

Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project

Massimo Federico et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

Add to Collection

Article Oncology

Revised response criteria for malignant lymphoma

Bruce D. Cheson et al.

JOURNAL OF CLINICAL ONCOLOGY (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.